Teva Pharmaceutical Industries Limited (TEVA) Stock Analysis
Teva Pharmaceutical Industries Limited is a global generic and specialty pharmaceutical manufacturer headquartered in Israel, with significant operations in the United States and Europe. Investors research Teva primarily to understand the dynamics of the generic drug market, its branded specialty portfolio (including migraine and multiple sclerosis treatments), and the company's ability to manage high debt levels while competing in price-sensitive markets.
Get a full AI research report on TEVA
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Teva Pharmaceutical Industries Limited do?
Teva generates revenue by developing, manufacturing, and distributing generic medicines across multiple dosage forms, as well as specialty branded products in CNS, respiratory, and oncology. The company also operates an active pharmaceutical ingredients business and contract manufacturing services, plus an out-licensing platform. Its branded portfolio includes treatments like COPAXONE (multiple sclerosis), AJOVY (migraine prevention), and AUSTEDO (tardive dyskinesia), which provide higher-margin revenue alongside its core generic business.
Bull case
- ✓Strong gross margin of 52% indicates pricing power and operational efficiency in manufacturing, even within the competitive generic sector.
- ✓Operating margin of 19.2% demonstrates the company's ability to convert revenue into operating profit despite generic price pressures.
- ✓Diversified product portfolio spanning generics, specialty brands, and CNS/respiratory/oncology focus areas reduces dependence on any single therapeutic area or market.
- ✓PEG ratio of 0.93 suggests valuation may be reasonable relative to growth expectations, compared to the forward P/E of 35.1.
- ✓Return on equity of 21.6% indicates the company generates meaningful returns on shareholder capital despite its leveraged balance sheet.
Bear case
- ✗Debt-to-equity ratio of 205.6 is extremely high, indicating substantial financial leverage and refinancing risk, particularly if interest rates remain elevated.
- ✗Forward P/E of 35.1 is significantly higher than the trailing P/E of 24.5, suggesting market expectations for near-term earnings growth that may not materialize.
- ✗Quick ratio of 0.527 is well below 1.0, raising concerns about the company's ability to meet short-term obligations without relying on inventory conversion.
- ✗Generic pharmaceutical markets face persistent pricing pressure from regulators and competitors, limiting margin expansion potential.
- ✗Zero dividend yield and zero payout ratio suggest the company is retaining all earnings, likely to service debt rather than reward shareholders.
TEVA valuation & financial health
Teva trades at a trailing P/E of 24.5 and forward P/E of 35.1, with a PEG ratio of 0.93 suggesting moderate valuation relative to growth. The company's 52% gross margin and 19.2% operating margin reflect operational strength, but profitability is constrained by a 205.6 debt-to-equity ratio—among the highest in the sector—which limits financial flexibility. The current ratio of 1.01 and quick ratio of 0.53 indicate tight liquidity, with the company dependent on ongoing cash generation to service debt. Return on equity of 21.6% is respectable, but much of this return flows to debt holders rather than equity holders, and the zero dividend payout reflects capital allocation prioritized toward deleveraging.
The bottom line
Teva presents a complex risk-reward profile centered on the tension between operational profitability and financial leverage. The company's strong margins and diversified specialty portfolio are offset by an unsustainably high debt load, tight liquidity, and forward earnings expectations that appear elevated relative to historical performance. Key factors to weigh include the trajectory of debt reduction, competitive pressures on generic pricing, and the commercial success of specialty brands like AJOVY and AUSTEDO. Investors should monitor quarterly debt metrics, cash flow generation, and management guidance on deleveraging timelines before forming a conviction.
Frequently asked questions
What does Teva Pharmaceutical Industries Limited do?
Teva develops, manufactures, and distributes generic medicines in multiple dosage forms, as well as specialty branded pharmaceuticals in areas like multiple sclerosis, migraine prevention, and oncology. The company also provides active pharmaceutical ingredients and contract manufacturing services globally.
Is TEVA a good stock to research?
Teva is worth researching if you're interested in understanding the generic pharmaceutical sector, specialty drug dynamics, or the challenges of managing a highly leveraged balance sheet in a price-competitive industry. The company's operational margins are strong, but financial structure presents material risks.
What are Teva's main branded products?
Key branded products include COPAXONE (glatiramer acetate for multiple sclerosis), AJOVY (migraine prevention), AUSTEDO (tardive dyskinesia), BENDEKA and TREANDA (chronic lymphocytic leukemia and non-Hodgkin's lymphoma). These specialty products generate higher margins than generics.
Is TEVA overvalued or undervalued?
Valuation depends on growth assumptions: the trailing P/E of 24.5 appears moderate, but the forward P/E of 35.1 implies significant near-term earnings growth that is not guaranteed. The PEG ratio of 0.93 suggests reasonable valuation relative to expected growth, but debt levels and liquidity constraints warrant caution.
What is Teva's debt situation?
Teva carries a debt-to-equity ratio of 205.6, among the highest in the pharmaceutical sector, which limits financial flexibility and increases refinancing risk. The company's quick ratio of 0.53 indicates tight short-term liquidity, making debt service dependent on ongoing cash generation.
Does Teva pay a dividend?
No, Teva currently pays no dividend (dividend yield of 0% and payout ratio of 0%), as the company prioritizes cash flow toward debt reduction rather than shareholder distributions.
Research TEVA with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.